|
1
|
Counsell CE and Grant R: Incidence studies
of primary and secondary intracranial tumors: a systematic review
of their methodology and results. J Neurooncol. 37:241–250. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Nazzaro JM and Neuwelt EA: The role of
surgery in the management of supratentorial intermediate and
high-grade astrocytomas in adults. J Neurosurg. 73:331–344. 1990.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Wood JR, Green SB and Shapiro WR: The
prognostic importance of tumor size in malignant gliomas: a
computed tomographic scan study by the Brain Tumor Cooperative
Group. J Clin Oncol. 6:338–343. 1988.PubMed/NCBI
|
|
4
|
Albert FK, Forsting M, Sartor K, Adams HP
and Kunze S: Early postoperative magnetic resonance imaging after
resection of malignant glioma: objective evaluation of residual
tumor and its influence on regrowth and prognosis. Neurosurgery.
34:45–61. 1994. View Article : Google Scholar
|
|
5
|
Devaux BC, O’Fallon JR and Kelly PJ:
Resection, biopsy, and survival in malignant glial neoplasms. A
retrospective study of clinical parameters, therapy, and outcome. J
Neurosurg. 78:767–775. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Curran WJ Jr, Scott CB, Horton J, et al:
Does extent of surgery influence outcome for astrocytoma with
atypical or anaplastic foci (AAF)? A report from three Radiation
Therapy Oncology Group (RTOG) trials. J Neurooncol. 12:219–227.
1992. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Walker MD, Alexander E Jr, Hun WE, et al:
Evaluation of BCNU and/or radiotherapy in the treatment of
anaplastic gliomas. A cooperative clinical trial. J Neurosurg.
49:333–343. 1978. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Walker MD, Strike TA and Sheline GE: An
analysis of dose-effect relationship in the radiotherapy of
malignant gliomas. Int J Radiat Oncol Biol Phys. 5:1725–1731. 1979.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Andersen AP: Postoperative irradiation of
glioblastomas. Results in a randomized series. Acta Radiol Oncol
Radiat Phys Biol. 17:475–484. 1978. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Kristiansen K, Hagen S, Kollevold T, et
al: Combined modality therapy of operated astrocytomas grade III
and IV. Confirmation of the value of postoperative irradiation and
lack of potentiation of bleomycin on survival time: a prospective
multicenter trial of the Scandinavian Glioblastoma Study Group.
Cancer. 47:649–652. 1981. View Article : Google Scholar
|
|
11
|
Laperriere N, Zuraw L and Cairncross G:
Radiotherapy for newly diagnosed malignant glioma in adults: a
systematic review. Radiother Oncol. 64:259–273. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Friedman HS, Kerby T and Calvert H:
Temozolomide and treatment of malignant glioma. Clin Cancer Res.
6:2585–2597. 2000.PubMed/NCBI
|
|
13
|
Watkins JM, Marshall DT, Patel S, et al:
High-dose radiotherapy to 78 Gy with or without temozolomide for
high grade gliomas. J Neurooncol. 93:343–348. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Stupp R, Hegi ME, Mason WP, et al: Effects
of radiotherapy with concomitant and adjuvant temozolomide versus
radiotherapy alone on survival in glioblastoma in a randomised
phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet
Oncol. 10:459–466. 2009.
|
|
15
|
Crombet T, Osorio M, Cruz T, et al: Use of
the humanized anti-epidermal growth factor receptor monoclonal
antibody h-R3 in combination with radiotherapy in the treatment of
locally advanced head and neck cancer patients. J Clin Oncol.
22:1646–1654. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Rodriguez MO, Rivero TC, del Castillo Bahi
R, et al: Nimotuzumab plus radiotherapy for unresectable
squamous-cell carcinoma of the head and neck. Cancer Biol Ther.
9:343–349. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
World Health Organization Classification
of Tumours. Pathology and genetics of tumours of the central
nervous system. World Health Organization, IARC Press; Lyon:
2000
|
|
18
|
Eisenhauer EA, Therasse P, Bogaerts J, et
al: New response evaluation criteria in solid tumours: revised
RECIST guideline (version 1.1). Eur J Cancer. 45:228–247. 2009.
View Article : Google Scholar
|
|
19
|
Behin A, Hoang-Xuan K, Carpentier AF and
Delattre JY: Primary brain tumours in adults. Lancet. 361:323–331.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Macdonald DR, Cascino TL, Schold SC Jr and
Cairncross JG: Response criteria for phase II studies of
supratentorial malignant glioma. J Clin Oncol. 8:1277–1280.
1990.PubMed/NCBI
|
|
21
|
Berg G, Blomquist E and Cavallin-Stahl E:
A systematic overview of radiation therapy effects in brain
tumours. Acta Oncol. 42:582–588. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Hegi ME, Diserens AC, Godard S, et al:
Clinical trial substantiates the predictive value of
O-6-methylguanine-DNA methyltransferase promoter methylation in
glioblastoma patients treated with temozolomide. Clin Cancer Res.
10:1871–1874. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Paz MF, Yaya-Tur R, Rojas-Marcos I, et al:
CpG island hypermethylation of the DNA repair enzyme
methyltransferase predicts response to temozolomide in primary
gliomas. Clin Cancer Res. 10:4933–4938. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Hegi ME, Diserens AC, Gorlia T, et al:
MGMT gene silencing and benefit from temozolomide in glioblastoma.
N Engl J Med. 352:997–1003. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Diaz MA, Blanco R, Garcia B, et al:
Biological activity in vitro of anti-epidermal growth factor
receptor monoclonal antibodies with different affinities. Hybridoma
(Larchmt). 26:423–431. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Ekstrand AJ, James CD, Cavenee WK, Seliger
B, Pettersson RF and Collins VP: Genes for epidermal growth factor
receptor, transforming growth factor alpha, and epidermal growth
factor and their expression in human gliomas in vivo. Cancer Res.
51:2164–2172. 1991.PubMed/NCBI
|
|
27
|
Bredel M, Pollack IF, Hamilton RL and
James CD: Epidermal growth factor receptor expression and gene
amplification in high-grade non-brainstem gliomas of childhood.
Clin Cancer Res. 5:1786–1792. 1999.PubMed/NCBI
|
|
28
|
Larysz D, Kula D, Kowal M, et al:
Epidermal growth factor receptor gene expression in high grade
gliomas. Folia Neuropathol. 49:28–38. 2011.PubMed/NCBI
|
|
29
|
Qin D, Ou G, Mo H, et al: Improved
efficacy of chemotherapy for glioblastoma by radiation-induced
opening of blood-brain barrier: clinical results. Int J Radiat
Oncol Biol Phys. 51:959–962. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Van Vulpen M, Kal HB, Taphoorn MJ and
El-Sharouni SY: Changes in blood-brain barrier permeability induced
by radiotherapy: Implications for timing of chemotherapy? (Review).
Oncol Rep. 9:683–688. 2002.PubMed/NCBI
|
|
31
|
Cao Y, Tsien CI, Shen Z, et al: Use of
magnetic resonance imaging to assess blood-brain/blood-glioma
barrier opening during conformal radiotherapy. J Clin Oncol.
23:4127–4136. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Ramos-Suzarte M, Rodriguez N, Oliva JP, et
al: 99mTc-labeled antihuman epidermal growth factor receptor
antibody in patients with tumors of epithelial origin: Part III.
Clinical trials safety and diagnostic efficacy. J Nucl Med.
40:768–775. 1999.
|
|
33
|
Ramos TC, Figueredo J, Catala M, et al:
Treatment of high-grade glioma patients with the humanized
anti-epidermal growth factor receptor (EGFR) antibody h-R3: report
from a phase I/II trial. Cancer Biol Ther. 5:375–379. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Giordano A, Rustum YM and Wenner CE: Cell
cycle: molecular targets for diagnosis and therapy: tumor
suppressor genes and cell cycle progression in cancer. J Cell
Biochem. 70:1–7. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Petit AM, Rak J, Hung MC, et al:
Neutralizing antibodies against epidermal growth factor and
ErbB-2/neu receptor tyrosine kinases down-regulate vascular
endothelial growth factor production by tumor cells in vitro and in
vivo: angiogenic implications for signal transduction therapy of
solid tumors. Am J Pathol. 151:1523–1530. 1997.
|
|
36
|
Kerbel RS, Viloria-Petit A, Okada F and
Rak J: Establishing a link between oncogenes and tumor
angiogenesis. Mol Med. 4:286–295. 1998.PubMed/NCBI
|
|
37
|
Gibson S, Tu S, Oyer R, Anderson SM and
Johnson GL: Epidermal growth factor protects epithelial cells
against Fas-induced apoptosis. Requirement for Akt activation. J
Biol Chem. 274:17612–17618. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Lammering G, Hewit TH, Hawkins WT, et al:
Epidermal growth factor receptor as a genetic therapy target for
carcinoma cell radiosensitization. J Natl Cancer Inst. 93:921–929.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Lammering G: Anti-epidermal growth factor
receptor strategies to enhance radiation action. Curr Med Chem
Anticancer Agents. 3:327–333. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Damiano V, Melisi D, Bianco C, et al:
Cooperative antitumor effect of multitargeted kinase inhibitor
ZD6474 and ionizing radiation in glioblastoma. Clin Cancer Res.
11:5639–5644. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Diaz MA, Rolff J, Lemm M, Fichtner I,
Perez R and Montero E: Radiosensitisation of U87MG brain tumours by
anti-epidermal growth factor receptor monoclonal antibodies. Br J
Cancer. 100:950–958. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Gorski DH, Beckett MA, Jaskowiak NT, et
al: Blockage of the vascular endothelial growth factor stress
response increases the antitumor effects of ionizing radiation.
Cancer Res. 59:3374–3378. 1999.PubMed/NCBI
|
|
43
|
Perrotte P, Matsumoto T, Inoue K, et al:
Anti-epidermal growth factor receptor antibody C225 inhibits
angiogenesis in human transitional cell carcinoma growing
orthotopically in nude mice. Clin Cancer Res. 5:257–265.
1999.PubMed/NCBI
|
|
44
|
Coleman CN and Stevenson MA: Biologic
basis for radiation oncology. Oncology (Williston Park).
10:399–415. 1996.
|
|
45
|
Bandyopadhyay D, Mandal M, Adam L,
Mendelsohn J and Kumar R: Physical interaction between epidermal
growth factor receptor and DNA-dependent protein kinase in
mammalian cells. J Biol Chem. 273:1568–1573. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Kwok TT and Sutherland RM: Cell cycle
dependence of epidermal growth factor induced radiosensitization.
Int J Radiat Oncol Biol Phys. 22:525–527. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Laderoute KR, Ausserer WA, Knapp AM, Grant
TD and Sutherland RM: Epidermal growth factor modifies cell cycle
control in A431 human squamous carcinoma cells damaged by ionizing
radiation. Cancer Res. 54:1407–1411. 1994.PubMed/NCBI
|
|
48
|
Huang SM and Harari PM: Modulation of
radiation response after epidermal growth factor receptor blockade
in squamous cell carcinomas: inhibition of damage repair, cell
cycle kinetics, and tumor angiogenesis. Clin Cancer Res.
6:2166–2174. 2000.
|
